β-secretase (BACE1) inhibitors with high in vivo efficacy suitable for clinical evaluation in Alzheimer's disease

Journal of Medicinal Chemistry

Volumn 56, Issue 10, 2013, Pages 3980-3995

  Hilpert, Hans ^a   Guba, Wolfgang ^a   Woltering, Thomas J ^a   Wostl, Wolfgang ^a   Pinard, Emmanuel ^a   Mauser, Harald ^a   Mayweg, Alexander V ^a   Rogers Evans, Mark ^a   Humm, Roland ^a   Krummenacher, Daniela ^a   Muser, Thorsten ^a   Schnider, Christian ^a   Jacobsen, Helmut ^a   Ozmen, Laurence ^a   Bergadano, Alessandra ^a   Banner, David W ^a   Hochstrasser, Remo ^a   Kuglstatter, Andreas ^a   David Pierson, Pascale ^a   Fischer, Holger ^a   Polara, Alessandra ^a   Narquizian, Robert ^a   more..

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

5 CHLORO PYRIDINE 2 CARBOXYLIC ACID [3 ( 2 AMINO 5,5 DIFLUORO 4 METHYL 5,6 DIHYDRO 4H [1,3]OXAZIN 4 YL) 4 FLUORO PHENYL] AMIDE; 5 CYANO PYRIDINE 2 CARBOXYLIC ACID [3 (2 AMINO 5,5 DIFLUORO 4 METHYL 5,6 DIHYDRO 4H [1,3]OXAZIN 4 YL) 4 FLUORO PHENYL] AMIDE; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; BETA SECRETASE INHIBITOR; OXAZINE DERIVATIVE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ARTICLE; CEREBROSPINAL FLUID; CONTROLLED STUDY; CRYSTALLOGRAPHY; DRUG EFFICACY; DRUG POTENCY; ENZYME ASSAY; FEMALE; IN VIVO STUDY; INHIBITION KINETICS; MOUSE; NONHUMAN; RAT;

ALZHEIMER DISEASE; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; ASPARTIC ACID ENDOPEPTIDASES; BRAIN CHEMISTRY; ENZYME INHIBITORS; FEMALE; FLUORINE; HUMANS; INDICATORS AND REAGENTS; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MODELS, MOLECULAR; OXAZINES; RATS; RATS, WISTAR; STRUCTURE-ACTIVITY RELATIONSHIP; X-RAY DIFFRACTION;

EID: 84878095153     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm400225m     Document Type: Article

References (62)

1. Jakob-Roetne, R.; Jacobsen, H. Alzheimer's Disease: From Pathology to Therapeutic Approaches Angew. Chem., Int. Ed. 2009, 48, 3030-3059
2. Hardy, J. A.; Higgins, G. A. Alzheimer's disease: the amyloid cascade hypothesis Science 1992, 256, 184-185
3. Selkoe, D. J. Cell biology of the amyloid β-protein precursor and the mechanism of Alzheimer's disease Annu. Rev. Cell Biol. 1994, 10, 373-403
4. Selkoe, D. J. The molecular pathology of Alzheimer's disease Neuron 1991, 6, 487-498
5. Selkoe, D. J. Toward a comprehensive theory for Alzheimer's disease. Hypothesis: Alzheimer's disease is caused by the cerebral accumulation and cytotoxicity of amyloid β-protein Ann. N. Y. Acad. Sci. 2000, 924, 17-25
6. Citron, M. Alzheimer's disease: strategies for disease modification Nature Rev. Drug Discovery 2010, 9, 387-398
7. Vassar, R. The β-secretase, BACE. A prime drug target for Alzheimer's disease J. Mol. Neurosci. 2001, 17, 157-170
8. Cole, S. L.; Vassar, R. BACE1 structure and function in health and Alzheimer's disease Curr. Alzheimer Res. 2008, 5, 100-120
9. Cai, H.; Wang, Y.; McCarthy, D.; Wen, H.; Borchelt, D. R.; Price, D. L.; Wong, P. C. BACE1 is the major beta-secretase for generation of Abeta peptides by neurons Nature Neurosci. 2001, 4, 233-234
10. Luo, Y.; Bolon, B.; Kahn, S.; Bennett, B. D.; Babu-Khan, S.; Denis, P.; Fan, W.; Kha, H.; Zhang, J.; Gong, Y.; Martin, L.; Louis, J.-C.; Yan, Q.; Richards, W. G.; Citron, M.; Vassar, R. Mice deficient in BACE1, the Alzheimer's β-secretase, have normal phenotype and abolished β-amyloid generation Nature Neurosci. 2001, 4, 231-232
11. McConlogue, L.; Buttini, M.; Anderson, J. P.; Brigham, E. F.; Chen, K. S.; Freedman, S. B.; Games, D.; Johnson-Wood, K.; Lee, M.; Zeller, M.; Liu, W.; Motter, R.; Sinha, S. Partial reduction of BACE1 has dramatic effects on Alzheimer plaque and synaptic pathology in APP transgenic mice J. Biol. Chem. 2007, 282, 26326-26334
12. Rabe, S.; Reichwald, J.; Ammaturo, D.; de, S. B.; Saftig, P.; Neumann, U.; Staufenbiel, M. The Swedish APP mutation alters the effect of genetically reduced BACE1 expression on the APP processing J. Neurochem. 2011, 119, 231-239
13. Hu, X.; Hicks, C. W.; He, W.; Wong, P.; Macklin, W. B.; Trapp, B. D.; Yan, R. Bace1 modulates myelination in the central and peripheral nervous system Nature Neurosci. 2006, 9, 1520-1525
14. Willem, M.; Garratt, A. N.; Novak, B.; Citron, M.; Kaufmann, S.; Rittger, A.; DeStrooper, B.; Saftig, P.; Birchmeier, C.; Haass, C. Control of Peripheral Nerve Myelination by the β-Secretase BACE1 Science 2006, 314, 664-666
15. Esterhazy, D.; Stuetzer, I.; Wang, H.; Rechsteiner, M. P.; Beauchamp, J.; Doebeli, H.; Hilpert, H.; Matile, H.; Prummer, M.; Schmidt, A.; Lieske, N.; Boehm, B.; Marselli, L.; Bosco, D.; Kerr-Conte, J.; Aebersold, R.; Spinas, G. A.; Moch, H.; Migliorini, C.; Stoffel, M. Bace2 Is a β Cell-Enriched Protease that Regulates Pancreatic β Cell Function and Mass Cell Metab. 2011, 14, 365-377
16. Sinha, S.; Anderson, J. P.; Barbour, R.; Basi, G. S.; Caccavello, R.; Davis, D.; Doan, M.; Dovey, H. F.; Frigon, N.; Hong, J.; Jacobson-Croak, K.; Jewett, N.; Keim, P.; Knops, J.; Lieberburg, I.; Power, M.; Tan, H.; Tatsuno, G.; Tung, J.; Schenk, D.; Seubert, P.; Suomensaari, S. M.; Wang, S.; Walker, D.; Zhao, J.; McConlogue, L.; John, V. Purification and cloning of amyloid precursor protein β-secretase from human brain Nature 1999, 402, 537-540
17. Vassar, R.; Bennett, B. D.; Babu-Khan, S.; Kahn, S.; Mendiaz, E. A.; Denis, P.; Teplow, D. B.; Ross, S.; Amarante, P.; Loeloff, R.; Luo, Y.; Fisher, S.; Fuller, J.; Edenson, S.; Lile, J.; Jarosinski, M. A.; Biere, A. L.; Curran, E.; Burgess, T.; Louis, J.-C.; Collins, F.; Treanor, J.; Rogers, G.; Citron, M. β-Secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE Science 1999, 286, 735-741
18. Yan, R.; Bienkowski, M. J.; Shuck, M. E.; Miao, H.; Tory, M. C.; Pauley, A. M.; Brashler, J. R.; Stratman, N. C.; Mathews, W. R.; Buhl, A. E.; Carter, D. B.; Tomasselli, A. G.; Parodi, L. A.; Heinrikson, R. L.; Gurney, M. E. Membrane-anchored aspartyl protease with Alzheimer's disease β-secretase activity Nature 1999, 402, 533-537
19. Lin, X.; Koelsch, G.; Wu, S.; Downs, D.; Dashti, A.; Tang, J. Human aspartic protease memapsin 2 cleaves the β-secretase site of β-amyloid precursor protein Proc. Natl. Acad. Sci. U. S. A. 2000, 97, 1456-1460
20. Hussain, I.; Powell, D.; Howlett, D. R.; Tew, D. G.; Meek, T. D.; Chapman, C.; Gloger, I. S.; Murphy, K. E.; Southan, C. D.; Ryan, D. M.; Smith, T. S.; Simmons, D. L.; Walsh, F. S.; Dingwall, C.; Christie, G. Identification of a Novel Aspartic Protease (Asp 2) as β-Secretase Mol. Cell. Neurosci. 1999, 14, 419-427
21. Probst, G.; Xu, Y.-z. Small-molecule BACE1 inhibitors: a patent literature review (2006-2011) Expert Opin. Ther. Pat. 2012, 22, 511-540
22. Cohen, N.; Banner, B. L. Synthesis of 2-amino-5,6-dihydro-4 H -1,3-thiazines and related compounds by acid catalyzed cyclization of allylic isothiuronium salts J. Heterocycl. Chem. 1977, 14, 717-723
23. Kobayashi, N.; Ueda, K.; Itoh, N.; Suzuki, S.; Sakaguchi, G.; Kato, A.; Yukimasa, A.; Hori, A.; Koriyama, Y.; Haraguchi, H.; Yasui, K.; Kanda, Y. Preparation of 2-aminodihydrothiazine derivatives as β-secretase inhibitors. WO2007049532A1, 2007.
24. Suzuki, Y.; Motoki, T.; Kaneko, T.; Takaishi, M.; Ishida, T.; Takeda, K.; Kita, Y.; Yamamoto, N.; Khan, A.; Dimopoulos, P. Preparation of condensed aminodihydrothiazine derivatives as inhibitors of β-site APP-cleaving enzyme 1 (BACE1). WO2009091016A1, 2009.
25. Audia, J. E.; Mergott, D. J.; Sheehan, S. M.; Watson, B. M. Preparation of aminodihydrothiazine derivatives for use as BACE inhibitors. WO2009134617A1, 2009.
26. Chen, J. J.; Zhong, W.; Yang, B.; Qian, W.; Lopez, P.; White, R.; Weiss, M.; Judd, T.; Powers, T.; Cheng, Y.; Dineen, T.; Epstein, O.; Low, J.; Marx, I.; Minatti, A. E.; Paras, N. A.; Potashman, M. Aminodihydrooxazine and aminodihydrothiazine spiro compounds as beta-secretase modulators and their their preparation and medical use. WO2011115928A1, 2011.
27. Clark, C. T.; Cook, A.; Gunawardana, I. W.; Hunt, K. W.; Kallan, N. C.; Siu, M.; Thomas, A. A.; Volgraf, M. Spirotetrahydronaphthalene derivatives as β-secretase inhibitors and their preparation and use for the treatment of neurodegenerative diseases. WO2011123674A1, 2011.
28. May, P. C.; Dean, R. A.; Lowe, S. L.; Martenyi, F.; Sheehan, S. M.; Boggs, L. N.; Monk, S. A.; Mathes, B. M.; Mergott, D. J.; Watson, B. M.; Stout, S. L.; Timm, D. E.; LaBell, E. S.; Gonzales, C. R.; Nakano, M.; Jhee, S. S.; Yen, M.; Ereshefsky, L.; Lindstrom, T. D.; Calligaro, D. O.; Cocke, P. J.; Hall, D. G.; Friedrich, S.; Citron, M.; Audia, J. E. Robust central reduction of amyloid-β in humans with an orally available, non-peptidic β-secretase inhibitor J. Neurosci. 2011, 31, 16507-16516
29. Woltering, T. J.; Wostl, W.; Hilpert, H.; Rogers-Evans, M.; Pinard, E.; Mayweg, A.; Banner, D. W.; Benz, J.; Narquizian, R.; Travagli, M.; Power, E.; Pollastrini, M.; Marconi, G.; Gabellieri, E.; Guba, W.; Mauser, H.; Andreini, M.; Jacobsen, H. BACE1 Inhibitors: A Head Group Scan on a Series of Amides. Submitted to Bioorg. Med. Chem. Lett.
30. Tang, T. P.; Ellman, J. A. The tert -Butanesulfinyl Group: An Ideal Chiral Directing Group and Boc-Surrogate for the Asymmetric Synthesis and Applications of β-Amino Acids J. Org. Chem. 1999, 64, 12-13
31. Sorochinsky, A.; Voloshin, N.; Markovsky, A.; Belik, M.; Yasuda, N.; Uekusa, H.; Ono, T.; Berbasov, D. O.; Soloshonok, V. A. Convenient Asymmetric Synthesis of β-Substituted α,α-Difluoro-β-amino Acids via Reformatskii Reaction between Davis' N -Sulfinylimines and Ethyl Bromodifluoroacetate J. Org. Chem. 2003, 68, 7448-7454
32. Tamura, Y.; Suzuki, S.; Tada, Y.; Yonezawa, S.; Fujikoshi, C.; Matsumoto, S.; Kooriyama, Y.; Ueno, T. Preparation of aminodihydrothiazine derivatives as BACE1 inhibitors. WO2008133274A1, 2008.
33. Masui, M.; Anan, K. Aminothiazine or aminooxazine derivative having amino linker for treatment of Alzheimer disease. WO2011058763A1, 2011.
34. Kunishima, M.; Morita, J.; Kawachi, C.; Iwasaki, F.; Terao, K.; Tani, S. Esterification of carboxylic acids with alcohols by 4-(4,6-dimethoxy-1,3,5- triazin-2-yl)-4-methylmorpholinium chloride (DMTMM) Synlett 1999, 1255-1256
35. Jaeger, V.; Muller, I.; Schohe, R.; Frey, M.; Ehrler, R.; Hafele, B.; Schroter, D. Syntheses via isoxazolines. Part 18. Old concepts and recent results on stereoselection at isoxazoline ring and adjacent centers Lect. Heterocycl. Chem. 1985, 8, 79-98
36. Banner, D.; Hilpert, H.; Mauser, H.; Mayweg, A. V.; Rogers-Evans, M. Preparation of oxazine derivatives as BACE2 inhibitors for treatment of diabetes. WO2011070029A1, 2011.
37. Masui, M.; Hori, A. Preparation of 2-amino-4-(aryl or heterocyclyl)-1,3-oxazine derivatives as β-secretase (BACE1) inhibitors. WO2011071135A1, 2011.
38. Ellard, J. M.; Farthing, C. N.; Hall, A. Preparation of fused aminodihydrooxazine derivatives as β-amyloid inhibitors and useful in the treatment of neurodegenerative disease caused by Aβ in particular Alzheimer-type dementia. WO2011009898A1, 2011.
39. Price, D. A.; Blagg, J.; Jones, L.; Greene, N.; Wager, T. Physicochemical drug properties associated with in vivo toxicological outcomes: a review Expert Opin. Drug Metab. Toxicol. 2009, 5, 921-931
40. Peters, J.-U.; Schnider, P.; Mattei, P.; Kansy, M. Pharmacological Promiscuity: Dependence on Compound Properties and Target Specificity in a Set of Recent Roche Compounds ChemMedChem 2009, 4, 680-686
41. Peters, J.-U.; Hert, J.; Bissantz, C.; Hillebrecht, A.; Gerebtzoff, G.; Bendels, S.; Tillier, F.; Migeon, J.; Fischer, H.; Guba, W.; Kansy, M. Can we discover pharmacological promiscuity early in the drug discovery process? Drug Discovery Today 2012, 17, 325-335
42. Mueller, K.; Faeh, C.; Diederich, F. Fluorine in Pharmaceuticals: Looking Beyond Intuition Science 2007, 317, 1881-1886
43. Banner, D.; Guba, W.; Hilpert, H.; Mauser, H.; Mayweg, A. V.; Narquizian, R.; Pinard, E.; Power, E.; Rogers-Evans, M.; Woltering, T.; Wostl, W. Preparation of 2-amino-5,5-difluoro-5,6-dihydro-4 H -oxazine derivatives as BACE1 and/or BACE2 inhibitors. WO2011069934A1, 2011.
44. Patel, S.; Vuillard, L.; Cleasby, A.; Murray, C. W.; Yon, J. Apo and Inhibitor Complex Structures of BACE (β-secretase) J. Mol. Biol. 2004, 343, 407-416
45. Stauffer, S. R.; Stanton, M. G.; Gregro, A. R.; Steinbeiser, M. A.; Shaffer, J. R.; Nantermet, P. G.; Barrow, J. C.; Rittle, K. E.; Collusi, D.; Espeseth, A. S.; Lai, M.-T.; Pietrak, B. L.; Holloway, M. K.; McGaughey, G. B.; Munshi, S. K.; Hochman, J. H.; Simon, A. J.; Selnick, H. G.; Graham, S. L.; Vacca, J. P. Discovery and SAR of isonicotinamide BACE-1 inhibitors that bind β-secretase in a N-terminal 10s-loop down conformation Bioorg. Med. Chem. Lett. 2007, 17, 1788-1792
46. Ostermann, N.; Eder, J.; Eidhoff, U.; Zink, F.; Hassiepen, U.; Worpenberg, S.; Maibaum, J.; Simic, O.; Hommel, U.; Gerhartz, B. Crystal Structure of Human BACE2 in Complex with a Hydroxyethylamine Transition-State Inhibitor J. Mol. Biol. 2006, 355, 249-261
47. Xu, Y.; Li, M.-j.; Greenblatt, H.; Chen, W.; Paz, A.; Dym, O.; Peleg, Y.; Chen, T.; Shen, X.; He, J.; Jiang, H.; Silman, I.; Sussman, J. L. Flexibility of the flap in the active site of BACE1 as revealed by crystal structures and molecular dynamics simulations Acta Crystallogr., Sect. D: Biol. Crystallogr. 2012, D68, 13-25
48. Banner, D. W.; Gsell, B.; Benz, J.; Bertschinger, J.; Burger, D.; Brack, S.; Cuppuleri, S.; Debulpaep, M.; Gast, A.; Grabulovski, D.; Hennig, M.; Hilpert, H.; Huber, W.; Kuglstatter, A.; Kusznir, E.; Laeremans, T.; Matile, H.; Miscenic, C.; a, Rufer, A.; Schlatter, D.; Staeyert, J.; Stihle, M.; Thoma, R.; Weber, M.; Ruf, A. Mapping the conformational space accessible to BACE2 using surface mutants and co-crystals with Fab-fragments, Fynomers, and Xaperones. Acta Crystallogr., Sect. D: Biol. Crystallogr., in press.
49. Jensen, H. H.; Lyngbye, L.; Jensen, A.; Bols, M. Stereoelectronic substituent effects in polyhydroxylated piperidines and hexahydropyridazines Chem.-Eur. J. 2002, 8, 1218-1226
50. Morgenthaler, M.; Schweizer, E.; Hoffmann-Roder, A.; Benini, F.; Martin, R. E.; Jaeschke, G.; Wagner, B.; Fischer, H.; Bendels, S.; Zimmerli, D.; Schneider, J.; Diederich, F.; Kansy, M.; Muller, K. Predicting and tuning physicochemical properties in lead optimization: amine basicities ChemMedChem 2007, 2, 1100-1115
51. Woltering, T. Halogen-alkyl-1,3 oxazines as BACE1 and/or BACE2 inhibitors and their preparation. WO2012168164A1, 2012.
52. VAMP, version 9.0; Accelrys Inc.: San Diego, CA; http://www.accelrys.com.
53. Rueeger, H.; Lueoend, R.; Rogel, O.; Rondeau, J.-M.; Mobitz, H.; Machauer, R.; Jacobson, L.; Staufenbiel, M.; Desrayaud, S.; Neumann, U. Discovery of Cyclic Sulfone Hydroxyethylamines as Potent and Selective β-Site APP-Cleaving Enzyme 1 (BACE1) Inhibitors: Structure-Based Design and in Vivo Reduction of Amyloid β-Peptides J. Med. Chem. 2012, 55, 3364-3386
54. Stamford, A. W.; Scott, J. D.; Li, S. W.; Babu, S.; Tadesse, D.; Hunter, R.; Wu, Y.; Misiaszek, J.; Cumming, J. N.; Gilbert, E. J.; Huang, C.; McKittrick, B. A.; Hong, L.; Guo, T.; Zhu, Z.; Strickland, C.; Orth, P.; Voigt, J. H.; Kennedy, M. E.; Chen, X.; Kuvelkar, R.; Hodgson, R.; Hyde, L. A.; Cox, K.; Favreau, L.; Parker, E. M.; Greenlee, W. J. Discovery of an Orally Available, Brain Penetrant BACE1 Inhibitor That Affords Robust CNS Aβ Reduction ACS Med. Chem. Lett. 2012, 3, 897-902
55. Truong, A. P.; Toth, G.; Probst, G. D.; Sealy, J. M.; Bowers, S.; Wone, D. W. G.; Dressen, D.; Hom, R. K.; Konradi, A. W.; Sham, H. L.; Wu, J.; Peterson, B. T.; Ruslim, L.; Bova, M. P.; Kholodenko, D.; Motter, R. N.; Bard, F.; Santiago, P.; Ni, H.; Chian, D.; Soriano, F.; Cole, T.; Brigham, E. F.; Wong, K.; Zmolek, W.; Goldbach, E.; Samant, B.; Chen, L.; Zhang, H.; Nakamura, D. F.; Quinn, K. P.; Yednock, T. A.; Sauer, J.-M. Design of an orally efficacious hydroxyethylamine (HEA) BACE-1 inhibitor in a preclinical animal model Bioorg. Med. Chem. Lett. 2010, 20, 6231-6236
56. Aronov, A. M. Ligand structural aspects of hERG channel blockade Curr. Top. Med. Chem. 2008, 8, 1113-1127
57. El, M. M.; Haseldonckx, M.; Mackie, C.; Meert, T.; Mercken, M. Method for the determination of the levels of β-amyloid peptide in the CSF sampled from freely moving rats J. Pharmacol. Toxicol. Methods 2005, 52, 229-233
58. Gruninger-Leitch, F.; Schlatter, D.; Kung, E.; Nelbock, P.; Dobeli, H. Substrate and inhibitor profile of BACE (β-secretase) and comparison with other mammalian aspartic proteases J. Biol. Chem. 2002, 277, 4687-4693
59. Martin, R. E.; Mohr, P.; Maerki, H. P.; Guba, W.; Kuratli, C.; Gavelle, O.; Binggeli, A.; Bendels, S.; Alvarez-Sanchez, R.; Alker, A.; Polonchuk, L.; Christ, A. D. Benzoxazole piperidines as selective and potent somatostatin receptor subtype 5 antagonists Bioorg. Med. Chem. Lett. 2009, 19, 6106-6113
60. Kuglstatter, A.; Stahl, M.; Peters, J.-U.; Huber, W.; Stihle, M.; Schlatter, D.; Benz, J.; Ruf, A.; Roth, D.; Enderle, T.; Hennig, M. Tyramine fragment binding to BACE-1 Bioorg. Med. Chem. Lett. 2008, 18, 1304-1307
61. Lanz, T. A.; Schachter, J. B. Demonstration of a common artifact in immunosorbent assays of brain extracts: development of a solid-phase extraction protocol to enable measurement of amyloid-β from wild-type rodent brain J. Neurosci. Methods 2006, 157, 71-81
62. Brockhaus, M.; Grunberg, J.; Rohrig, S.; Loetscher, H.; Wittenburg, N.; Baumeister, R.; Jacobsen, H.; Haass, C. Caspase-mediated cleavage is not required for the activity of presenilins in amyloidogenesis and NOTCH signaling NeuroReport 1998, 9, 1481-1486